Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8432254 | 0.75 | AR (0.47) | CYP2C19TSHRARALDH1A1 | |
| SCHEMBL4581557 | 0.75 | SYK (0.50) | ALDH1A1 | |
| SCHEMBL6154479 | 0.74 | IMPDH2 (0.60) | SRCEGFRERBB2PRKCQIMPDH2 | |
| SCHEMBL6431488 | 0.74 | KDM4E (0.56) | SRCEGFRERBB2TSHRAR | |
| SCHEMBL8436504 | 0.74 | EGFR (0.47) | SRCEGFRERBB2AR | |
| SCHEMBL17631638 | 0.74 | AR (0.52) | SRCEGFRERBB2AR | |
| SCHEMBL15364954 | 0.72 | AR (0.49) | SRCAR | |
| SCHEMBL15337643 | 0.72 | AR (0.47) | CYP2C19ARALDH1A1 | |
| SCHEMBL5648357 | 0.72 | ICMT (0.53) | CYP2C19ARALDH1A1 | |
| SCHEMBL6157998 | 0.71 | IMPDH2 (0.51) | SRCEGFRERBB2PRKCQIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | claimed |
| WO-2008024963-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008024963-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | RB1, MKI67, CCNB1 | SRC 1098/4885EGFR 906/4885ERBB2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.